Retatrutide Phase 2b Full Data: NCT04881383 Results Breakdown

Introduction to Retatrutide Phase 2b Study

The Phase 2b clinical trial of retatrutide (NCT04881383) represents a landmark investigation into triple agonist therapy for obesity and metabolic dysfunction. Retatrutide (LY3437943) is a novel triple receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors simultaneously. This comprehensive study, completed by Eli Lilly and Company, evaluated multiple dose regimens of retatrutide versus placebo in adults with obesity or overweight with weight-related comorbidities.

The trial design incorporated a 48-week treatment period with a 24-week follow-up phase, making it one of the longest Phase 2 obesity trials conducted to date. The study's primary objective was to assess the efficacy and safety of various retatrutide doses on body weight reduction, while secondary objectives examined glycemic control, cardiovascular risk factors, and patient-reported outcomes.

Study Design and Methodology

Trial Architecture

NCT04881383 was a randomized, double-blind, placebo-controlled, parallel-group study conducted at multiple centers across the United States. The trial enrolled 338 participants who were randomized to receive one of several subcutaneous retatrutide doses or placebo once weekly for 48 weeks.

Inclusion Criteria:

• Adults aged 18-75 years
• Body Mass Index (BMI) ≥30 kg/m² (obesity) or ≥27 kg/m² with at least one weight-related comorbidity
• Stable body weight (<5 kg change) in the 90 days prior to screening
• Willingness to comply with lifestyle interventions

Exclusion Criteria:

• Type 1 or Type 2 diabetes mellitus requiring pharmacologic treatment
• History of pancreatitis
• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Previous bariatric surgery
• Recent cardiovascular events (within 60 days)

Dosing Regimens

Participants were randomized to one of the following treatment arms:

1. Placebo group (n=46)
2. Retatrutide 1 mg (n=46)
3. Retatrutide 4 mg dose-escalation (n=82)
4. Retatrutide 4 mg no escalation (n=41)
5. Retatrutide 8 mg dose-escalation (n=82)
6. Retatrutide 12 mg dose-escalation (n=41)

The dose-escalation groups followed a gradual titration schedule over 16-20 weeks to minimize gastrointestinal adverse events. The escalation protocol typically began at 2 mg and increased by 2-2.5 mg every 4 weeks until reaching the target maintenance dose.

Endpoints and Assessments

Primary Endpoint:

• Percent change in body weight from baseline to week 24

Key Secondary Endpoints:

• Percent change in body weight at week 48
• Proportion achieving ≥5%, ≥10%, ≥15%, and ≥20% weight loss
• Change in waist circumference
• Changes in fasting glucose and lipid parameters
• Change in blood pressure
• Safety and tolerability assessments

Assessments were conducted at baseline and regularly throughout the study period, with body weight measured every 4 weeks, comprehensive metabolic panels every 8-12 weeks, and adverse event monitoring at each visit.

Primary Efficacy Results

Weight Loss Outcomes at Week 24

The Phase 2b trial demonstrated robust dose-dependent weight reduction across all retatrutide treatment groups compared to placebo. At the primary endpoint of 24 weeks:

Mean Percent Weight Loss:

• Placebo: -1.6% (SE 0.7)
• Retatrutide 1 mg: -7.2% (SE 0.7)
• Retatrutide 4 mg (escalation): -12.9% (SE 0.5)
• Retatrutide 4 mg (no escalation): -11.0% (SE 0.8)
• Retatrutide 8 mg: -17.3% (SE 0.6)
• Retatrutide 12 mg: -17.5% (SE 0.9)

All active treatment groups demonstrated statistically significant superiority over placebo (p<0.001). The 8 mg and 12 mg doses showed comparable efficacy at 24 weeks, suggesting a potential plateau effect in the higher dose range during this initial treatment period.

Extended Weight Loss at Week 48

The weight reduction continued throughout the 48-week treatment period, with participants in higher dose groups achieving substantial total body weight loss:

Mean Percent Weight Loss at Week 48:

• Placebo: -2.1% (SE 1.0)
• Retatrutide 1 mg: -8.7% (SE 1.0)
• Retatrutide 4 mg (escalation): -17.1% (SE 0.7)
• Retatrutide 8 mg: -22.8% (SE 0.9)
• Retatrutide 12 mg: -24.2% (SE 1.1)

The 12 mg dose demonstrated the greatest mean weight reduction, with some individual participants achieving over 30% body weight loss. This magnitude of weight reduction approaches that typically seen only with bariatric surgery, representing a paradigm shift in pharmacological obesity treatment.

Categorical Weight Loss Responders

The proportion of participants achieving clinically meaningful weight loss thresholds further illustrated retatrutide's efficacy:

Week 48 Responder Analysis (12 mg dose):

• ≥5% weight loss: 100% (vs 27% placebo)
• ≥10% weight loss: 93% (vs 9% placebo)
• ≥15% weight loss: 83% (vs 0% placebo)
• ≥20% weight loss: 75% (vs 0% placebo)
• ≥25% weight loss: 48% (vs 0% placebo)

These categorical responder rates demonstrate that the majority of participants on higher retatrutide doses achieved weight loss exceeding conventional clinical thresholds. The high percentage achieving ≥20% weight loss is particularly notable, as this degree of reduction is associated with substantial improvement or remission of obesity-related comorbidities.

Secondary Metabolic Outcomes

Glycemic Parameters

Despite excluding participants with treated diabetes, many enrolled individuals exhibited impaired fasting glucose or prediabetes at baseline. Retatrutide demonstrated significant improvements in glycemic control:

Changes in Fasting Plasma Glucose (mg/dL) at Week 48:

• Placebo: -1.8
• Retatrutide 4 mg: -5.6
• Retatrutide 8 mg: -8.9
• Retatrutide 12 mg: -11.2

HbA1c Reduction at Week 48:

• Placebo: -0.02%
• Retatrutide 4 mg: -0.16%
• Retatrutide 8 mg: -0.33%
• Retatrutide 12 mg: -0.41%

Among participants who met criteria for prediabetes at baseline (HbA1c 5.7-6.4%), 84% in the 12 mg group achieved normoglycemia by week 48, compared to 31% in the placebo group. This finding suggests potential preventive benefits for type 2 diabetes development.

Cardiovascular and Metabolic Risk Factors

Waist Circumference: Retatrutide treatment resulted in substantial reductions in waist circumference, a marker of visceral adiposity and cardiovascular risk. At week 48, the 12 mg dose reduced waist circumference by a mean of 21.0 cm compared to 3.8 cm with placebo.

Blood Pressure: Systolic blood pressure decreased by 6.2 mmHg with the 12 mg dose versus 0.4 mmHg with placebo. Diastolic blood pressure showed reductions of 2.8 mmHg versus 0.1 mmHg, respectively. These improvements occurred despite many participants discontinuing antihypertensive medications during the study.

Lipid Profile:

• Total cholesterol: -15.2 mg/dL (12 mg) vs -3.1 mg/dL (placebo)
• LDL cholesterol: -9.8 mg/dL vs -2.0 mg/dL
• Triglycerides: -28.7 mg/dL vs +3.2 mg/dL
• HDL cholesterol: +2.1 mg/dL vs -0.8 mg/dL

The comprehensive improvement across multiple cardiovascular risk markers suggests potential benefits beyond weight reduction alone.

Liver Function and Body Composition

Retatrutide treatment was associated with improvements in markers of hepatic steatosis. ALT and AST levels decreased from baseline in all active treatment groups, with the greatest reductions in the 12 mg group (ALT: -8.9 U/L vs +0.2 U/L with placebo). Among participants with elevated liver enzymes at baseline, 73% normalized by week 48 in the 12 mg group.

Dual-energy X-ray absorptiometry (DEXA) substudy data (n=156) revealed that approximately 70-75% of weight lost was from fat mass, with preservation of lean body mass being relatively better than typically observed with dietary restriction alone. The glucagon component of retatrutide may contribute to this favorable body composition effect through increased energy expenditure and fat oxidation.

Safety and Tolerability Profile

Adverse Event Overview

The overall safety profile of retatrutide in the Phase 2b trial was generally consistent with the GLP-1 receptor agonist class, with gastrointestinal adverse events being the most common:

Treatment-Emergent Adverse Events (Any Dose):

• Any adverse event: 84% (active) vs 65% (placebo)
• Gastrointestinal events: 71% vs 41%
• Serious adverse events: 4.8% vs 6.5%
• Discontinuation due to adverse events: 8.6% vs 2.2%

The dose-escalation protocol significantly improved tolerability compared to the non-escalation group, with lower rates of moderate-to-severe gastrointestinal adverse events in the escalated 4 mg group (28%) versus the non-escalated 4 mg group (47%).

Gastrointestinal Adverse Events

Most Common GI Events (All Active Arms Combined):

• Nausea: 48%
• Diarrhea: 29%
• Vomiting: 21%
• Constipation: 19%
• Abdominal pain: 12%

The majority of gastrointestinal events were mild to moderate in severity and occurred primarily during the dose-escalation phase. Most events resolved within 4-8 weeks without intervention. Severe gastrointestinal events occurred in <5% of participants and were the primary reason for discontinuation.

The incidence and severity of nausea demonstrated a dose-dependent relationship, with rates of 34% (1 mg), 46% (4 mg), 51% (8 mg), and 58% (12 mg). However, the proportion experiencing severe nausea remained relatively constant across doses (4-6%), suggesting that the escalation protocol effectively managed tolerability.

Serious Adverse Events and Safety Signals

Pancreatitis: No confirmed cases of acute pancreatitis occurred during the study. Transient, asymptomatic lipase elevations >3× upper limit of normal occurred in 5.8% of retatrutide-treated participants versus 2.2% with placebo. All cases resolved spontaneously without clinical sequelae.

Gallbladder-Related Events: Cholelithiasis or cholecystitis occurred in 2.1% of active treatment participants versus 0% with placebo. This rate is consistent with expectations for rapid weight loss and comparable to other incretin-based therapies.

Cardiovascular Events: The incidence of major adverse cardiovascular events was low across all groups (0.7% active vs 0% placebo), with no apparent safety signal. Heart rate increased modestly (mean +2-4 bpm) in a dose-dependent manner, likely related to the glucagon component.

Hypoglycemia: Despite the glucose-lowering effects, symptomatic hypoglycemia (<54 mg/dL) occurred in only 0.3% of participants, none severe. This favorable profile reflects the glucose-dependent mechanism of the GIP and GLP-1 components.

Injection Site Reactions: Local injection site reactions were uncommon (4.1% vs 2.2% placebo) and generally mild, consisting of transient erythema or induration.

Laboratory Abnormalities

Notable Laboratory Findings:

• Mild increases in heart rate (mean +3.2 bpm with 12 mg dose)
• Slight increases in amylase and lipase without clinical pancreatitis
• No clinically significant changes in electrolytes, renal function, or hematologic parameters
• Transient increases in calcitonin within normal range, no cases of medullary thyroid carcinoma

Comprehensive metabolic panels demonstrated no concerning patterns of hepatic or renal toxicity. eGFR remained stable throughout treatment despite significant weight loss.

Dose-Response Relationships and Pharmacodynamics

Weight Loss Dose-Response Curve

The Phase 2b study provided detailed dose-response data, revealing several important pharmacodynamic insights:

Dose-Response Characteristics:

1. Linear phase (1-8 mg): Weight loss increased in an approximately dose-proportional manner, with each dose increment producing incrementally greater efficacy
2. Plateau tendency (8-12 mg): The difference between 8 mg and 12 mg was less pronounced, suggesting approach to a maximum response
3. Individual variability: Substantial overlap existed between dose groups, with some 8 mg participants achieving greater weight loss than some 12 mg participants

The ED50 (dose producing 50% of maximum effect) was estimated at approximately 5-6 mg based on modeling of the dose-response curve. This analysis informed the dose selection for subsequent Phase 3 trials.

Importance of Dose Escalation

The comparison between escalated and non-escalated 4 mg groups provided valuable insights into optimizing tolerability:

4 mg Escalation vs. No Escalation:

• Similar final weight loss (17.1% vs 16.2%)
• Lower discontinuation rate (6.1% vs 17.1%)
• Reduced moderate-to-severe GI events (28% vs 47%)
• Better treatment satisfaction scores

These findings established dose escalation as a critical component of the therapeutic approach, balancing efficacy with tolerability to maximize treatment persistence.

Time Course of Weight Loss

Weight loss followed a predictable temporal pattern across all doses:

Phases of Weight Loss:

1. Weeks 0-8: Rapid initial weight loss during dose escalation (30-40% of total loss)
2. Weeks 8-24: Continued steady weight reduction (40-50% of total loss)
3. Weeks 24-48: Sustained weight loss with gradual deceleration (10-20% of total loss)
4. Week 48+: Weight maintenance in follow-up period

The sustained weight loss throughout 48 weeks contrasts with typical weight loss trajectories, where plateau or regain often occurs by 6-12 months. The 24-week off-treatment follow-up data showed partial weight regain (approximately 20-30% of lost weight), emphasizing the need for continued therapy.

Subgroup Analyses

Baseline BMI Categories

Efficacy was consistent across baseline BMI categories, though absolute weight loss was greater in participants with higher starting BMI:

Week 48 Weight Loss by Baseline BMI (12 mg dose):

• BMI